Filing Details
- Accession Number:
- 0000914475-25-000067
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-02-14 18:35:09
- Reporting Period:
- 2025-02-12
- Filing Date:
- 2025-02-14
- Accepted Time:
- 2025-02-14 18:35:09
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 914475 | Neurocrine Biosciences Inc | NBIX | Biological Products, (No Disgnostic Substances) (2836) | 330525145 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1894425 | Jude Onyia | 12780 El Camino Real San Diego CA 92130 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-02-13 | 2,717 | $0.00 | 18,278 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-02-13 | 1,432 | $116.83 | 16,846 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2025-02-13 | 2,690 | $0.00 | 19,536 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-02-13 | 1,447 | $116.75 | 18,089 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option | Acquisiton | 2025-02-12 | 54,645 | $0.00 | 54,645 | $117.18 |
| Common Stock | Restricted Stock Unit | Acquisiton | 2025-02-12 | 10,241 | $0.00 | 10,241 | $0.00 |
| Common Stock | Restricted Stock Unit | Disposition | 2025-02-13 | 2,717 | $0.00 | 2,717 | $0.00 |
| Common Stock | Restricted Stock Unit | Disposition | 2025-02-13 | 2,690 | $0.00 | 2,690 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 54,645 | 2035-02-12 | No | 4 | A | Direct | |
| 10,241 | No | 4 | A | Direct | ||
| 5,434 | No | 4 | M | Direct | ||
| 8,070 | No | 4 | M | Direct |
Footnotes
- The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.02 to $118.34. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.02 to $118.36. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
- The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029.
- This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,717 shares on February 13, 2024, vested as to 2,717 shares on February 13, 2025, and will vest as to 2,717 shares on February 13, 2026, and 2,717 shares on February 13, 2027, subject to the terms and conditions of the award.
- This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,690 shares on February 13, 2025, and will vest as to 2,690 shares on February 13, 2026, 2,690 shares on February 13, 2027, and 2,690 shares on February 13, 2028, subject to the terms and conditions of the award.
Billionaire Hedge Funds
